Submission of NDA in the US for induction of remission of ulcerative colitis planned for December 2011 Lainate (September 20, 2011) – Cosmo Pharmaceuticals SpA, (SIX: COPN), today announced that …
Cosmo announces the additional approval of LIALDA in the U.S. for the maintenance of remission in patients with ulcerative colitis
LAINATE, ITALY (July 19, 2011) Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that Shire plc (LSE: SHP, NASDAQ: SHPGY), announced that the U.S. Food and Drug Administration (FDA) approved …
Cosmo announces live transmission of Blu-Colonoscopy at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano
LAINATE (June 16, 2011) Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that its Methylene Blue MMX® for the diagnosis of lesions, polyps and adenomas in the colon will be presented in a live …
Cosmo announces filing of Budesonide MMX® for treatment of mild to moderate active Ulcerative Colitis in Europe
LAINATE (May 31, 2011) Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that, based on the successfully concluded clinical trials in the US and EU, it had filed the documentation required for …
Cosmo reports good 2010 operational results
Strategic goals met - Confident outlook for 2011 Lainate, Italy – 25 March 2011 – Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced its results for the year ended 31 December 2010. Financial …